Doxepin Shortage: What Providers and Prescribers Need to Know in 2026

Doxepin has been used in clinical practice since 1969 — yet some of your patients may be having increasing difficulty filling their prescriptions in 2026. While doxepin is not currently on the FDA's official drug shortage list, localized supply gaps persist across multiple formulations, and providers are fielding calls from patients who cannot locate their medication. This guide offers a clinical framework for managing these situations.

Current Availability Status (2026)

As of early 2026, doxepin is not formally listed on either the FDA Drug Shortage Database or the ASHP shortage tracker. However, availability varies significantly by region, pharmacy type, and specific formulation. Patients on higher-dose capsules (75 mg, 100 mg, 150 mg) and those requiring the oral concentrate are most likely to encounter fulfillment challenges. Silenor brand tablets (3 mg/6 mg) may not be stocked by all retail pharmacies, though generic doxepin tablets in the same doses are generally available.

Root Causes of Doxepin Supply Instability

Understanding the upstream causes helps anticipate future disruptions:

• Concentrated generic supplier market: As a decades-old drug with modest market size, doxepin attracts few generic manufacturers. This means supply chain fragility is structurally embedded — any manufacturing disruption has outsized effects on availability.
• Brand discontinuation: Sinequan (the original Pfizer brand) was discontinued, eliminating a secondary source and leaving the market wholly dependent on generics for the capsule and solution formulations.
• Increased mental health prescription volume: Post-pandemic demand for antidepressants and sleep medications has not returned to pre-pandemic baselines. Doxepin prescribing increased, particularly for insomnia, as telehealth expanded access to psychiatry and sleep medicine.

Clinical Considerations When Doxepin Is Unavailable

When a patient cannot fill their doxepin prescription, the appropriate response depends on the indication:

For Depression and Anxiety

Doxepin is rarely a first-line agent for depression or anxiety in 2026. If a patient cannot fill their prescription, consider:

• Cross-taper to another TCA: Amitriptyline is the most structurally similar and commonly available alternative. Nortriptyline (the active metabolite of amitriptyline) has a somewhat better side-effect profile with less sedation and anticholinergic burden. Dose equivalence varies — consult conversion guidelines.
• Transition to an SSRI or SNRI: If doxepin was chosen primarily for its sedating properties in a patient with comorbid insomnia, consider adding a non-sedating antidepressant with a separate sleep agent. SSRIs (sertraline, escitalopram) or SNRIs (venlafaxine, duloxetine) are first-line for depression/anxiety.
• Gradual taper, not abrupt stop: If a patient must discontinue, prescribe a structured taper. TCAs can cause discontinuation syndrome with abrupt cessation, including GI symptoms, insomnia, irritability, and flu-like symptoms.

For Insomnia (Silenor / Low-Dose Doxepin)

Doxepin's FDA approval for insomnia at 3–6 mg is based on its highly selective H1 antagonism at these doses — different from its antidepressant mechanism at higher doses. Key clinical considerations when substituting:

• Trazodone 50–150 mg at bedtime: Not FDA-approved for insomnia but widely used off-label. Not a controlled substance. Reasonable alternative, particularly in patients with comorbid depression or anxiety.
• Mirtazapine 7.5–15 mg at bedtime: Strong sedation at low doses via H1 and 5-HT2 antagonism. Not a controlled substance. Best when comorbid depression or appetite loss is present.
• Orexin antagonists (suvorexant, lemborexant): Mechanistically different approach — block wakefulness promotion pathways. Schedule IV/V controlled substances. Good for sleep maintenance specifically. Higher cost than doxepin generics.
• CBT-I: For patients who cannot tolerate or access pharmacologic sleep aids, cognitive behavioral therapy for insomnia (CBT-I) has Level I evidence and is recommended as first-line by the American College of Physicians and the American Academy of Sleep Medicine.

Key Drug Safety Reminders When Switching

• Allow a 14-day washout if transitioning to or from an MAOI
• Monitor QTc if switching to another QT-prolonging agent
• CYP2D6 poor metabolizers have reduced doxepin metabolism — consider dose reductions; this also applies to alternatives metabolized by CYP2D6 (nortriptyline, amitriptyline)
• TCAs as a class require cardiac monitoring at higher doses, particularly in older patients — ECG for baseline QTc assessment before initiation is standard practice

Helping Patients Who Are Struggling to Fill Doxepin

Consider directing patients to medfinder — a service that contacts pharmacies near the patient to locate which ones can fill their specific prescription. This can save patients hours of calling around and may prevent unnecessary medication switches.

You can also proactively prescribe: "doxepin [dose] capsules/tablets — may substitute generic" to give pharmacists maximum flexibility in sourcing an equivalent product. For insomnia, indicating that either 3 mg or 6 mg tablets (brand or generic) are acceptable gives the pharmacist multiple inventory options to work with.

For patient-facing information, see our doxepin shortage update for patients which covers what patients should do when their pharmacy is out of stock.